Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
Open Access
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in Research and Practice in Thrombosis and Haemostasis
- Vol. 1 (2), 172-179
- https://doi.org/10.1002/rth2.12036
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Bayer
This publication has 29 references indexed in Scilit:
- Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studiesThrombosis Journal, 2013
- Simple frailty score predicts postoperative complications across surgical specialtiesThe American Journal of Surgery, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosisJournal of Vascular Surgery, 2011
- Redefining Geriatric Preoperative Assessment Using Frailty, Disability and Co-MorbidityAnnals of Surgery, 2009
- The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillationAge and Ageing, 2008
- Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE RegistryThrombosis and Haemostasis, 2008
- A global clinical measure of fitness and frailty in elderly peopleCMAJ : Canadian Medical Association Journal, 2005